KCT0004476
Completed
未知
Clinical utility of [F-18]PSMA-1007 PET/CT (positron emission tomography/computed tomography) in evaluating preoperative staging of prostate cancer before radical prostatectomy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yonsei University Health System, Severance Hospital
- Enrollment
- 126
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Inclusion Criteria
- •(1\) An adult male aged 20 years or older who is planning to undergo radical prostatectomy for intermediate to high risk prostate cancer.
- •(2\) The subject can and will follow the clinical trial procedure, and the subject obtains a signed and dated patient consent.
Exclusion Criteria
- •2\. Exclusion Criteria
- •(1\) Patients who do not agree with the study
- •(2\) Patients with hypersensitivity to radioisotopes
- •(3\) Participants in other studies at the time of screening who may influence \[F\-18] PSMA\-1007 image acquisition.
- •(4\) A person deemed difficult to conduct a clinical trial due to a serious medical condition by the researcher.
- •(5\) Those who have had a mental illness that is difficult to scan PET/CT.
- •(6\) Vulnerable subjects (researchers or students involved in the research, researchers or students of the researchers involved in the research, the family of the subjects)
- •(7\) Other investigator determined to be unsuitable for participation in this clinical trial
- •(8\) Those who were found to be difficult to remove surgically on the areas that appeared positive on PET imaging.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate CancerProstate CancerProstate Cancer RecurrentNCT04742361ABX advanced biochemical compounds GmbH136
Recruiting
Not Applicable
Evaluation of the use of PET/CT in Adenoid Cystic Carcinoma (ADC)RBR-84nmnm9Eduardo Nóbrega Pereira Lima
Not yet recruiting
Not Applicable
Prostate Cancer 18F-PSMA-1007 PET/CT Access TrialProstate CancerNCT06489496Alberta Health services1,000
Recruiting
Phase 3
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate CancerProstate CancerNCT06122584ABX advanced biochemical compounds GmbH380
Active, not recruiting
Phase 1
PSMA vs FACBC compared to PLND for lymph node staging in primary prostate cancerProstate cancer (PCa) is the most common malignancy amongst men in Westerncountries. In order to select the most suitable treatment for patients diagnosed with PCa, it is importantto stage accurately. Both 18F-PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT are currently mostly used to detectrecurrence in treated PCa, while the diagnostic value in detecting lymph node metastasis in primaryprostate cancer is not yet clear.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2019-004045-33-NLCatharina Hospital Eindhoven70